CY1125254T1 - Μεθοδοι αγωγης μητρικων ινομυωματων και ενδομητριωσης - Google Patents
Μεθοδοι αγωγης μητρικων ινομυωματων και ενδομητριωσηςInfo
- Publication number
- CY1125254T1 CY1125254T1 CY20221100390T CY221100390T CY1125254T1 CY 1125254 T1 CY1125254 T1 CY 1125254T1 CY 20221100390 T CY20221100390 T CY 20221100390T CY 221100390 T CY221100390 T CY 221100390T CY 1125254 T1 CY1125254 T1 CY 1125254T1
- Authority
- CY
- Cyprus
- Prior art keywords
- subject
- methods
- reducing
- uterine fibroids
- adenomyosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US201662402034P | 2016-09-30 | 2016-09-30 | |
| US201662402055P | 2016-09-30 | 2016-09-30 | |
| US201762492839P | 2017-05-01 | 2017-05-01 | |
| US201762528409P | 2017-07-03 | 2017-07-03 | |
| PCT/EP2017/074907 WO2018060501A2 (en) | 2016-09-30 | 2017-09-29 | Methods of treating uterine fibroids and endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125254T1 true CY1125254T1 (el) | 2024-02-16 |
Family
ID=60915460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100390T CY1125254T1 (el) | 2016-09-30 | 2022-06-02 | Μεθοδοι αγωγης μητρικων ινομυωματων και ενδομητριωσης |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11033551B2 (enExample) |
| EP (2) | EP4094766B1 (enExample) |
| JP (1) | JP7043503B2 (enExample) |
| CN (1) | CN110312512B (enExample) |
| AU (2) | AU2017336363B2 (enExample) |
| BR (1) | BR112019006227A2 (enExample) |
| CA (1) | CA3038879A1 (enExample) |
| CY (1) | CY1125254T1 (enExample) |
| DK (1) | DK3518933T4 (enExample) |
| ES (2) | ES2912929T5 (enExample) |
| FI (1) | FI3518933T4 (enExample) |
| HR (1) | HRP20220708T4 (enExample) |
| HU (2) | HUE059101T2 (enExample) |
| IL (2) | IL300580B2 (enExample) |
| LT (1) | LT3518933T (enExample) |
| MD (1) | MD3518933T4 (enExample) |
| MX (1) | MX2019003726A (enExample) |
| NZ (1) | NZ752916A (enExample) |
| PL (2) | PL3518933T5 (enExample) |
| PT (1) | PT3518933T (enExample) |
| RS (1) | RS63300B2 (enExample) |
| SI (1) | SI3518933T2 (enExample) |
| SM (1) | SMT202200254T1 (enExample) |
| WO (1) | WO2018060501A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| EP4509173A3 (en) | 2017-06-05 | 2025-06-04 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| US11980621B2 (en) | 2017-06-05 | 2024-05-14 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| JP2021531236A (ja) * | 2018-04-19 | 2021-11-18 | アッヴィ・インコーポレイテッド | 重度の月経出血を治療する方法 |
| MA54058A (fr) * | 2018-10-29 | 2021-09-08 | ObsEva SA | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
| RU2711658C1 (ru) * | 2019-04-16 | 2020-01-20 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| EP4009977A2 (en) * | 2019-08-08 | 2022-06-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN115279769A (zh) | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| EP4041738A1 (en) * | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| EP4107525A4 (en) * | 2020-02-19 | 2024-08-14 | Aspira Women's Health Inc. | Compositions for endometriosis assessment having improved specificity |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| EP4243829A1 (en) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| EP4419530A1 (en) | 2021-10-18 | 2024-08-28 | Sumitomo Pharma Switzerland GmbH | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN117069735A (zh) * | 2022-05-10 | 2023-11-17 | 北京海美源医药科技有限公司 | 一种高效合成瑞卢戈利的方法和其应用 |
| WO2024015934A2 (en) * | 2022-07-13 | 2024-01-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of diagnostic screening and early detection of adenomyosis |
| WO2024102620A2 (en) * | 2022-11-09 | 2024-05-16 | Tempest Therapeutics, Inc. | Triazolone compounds and uses thereof |
| WO2025106820A1 (en) * | 2023-11-16 | 2025-05-22 | University Of South Florida | Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub) |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US402055A (en) | 1889-04-23 | Water-motor | ||
| US402034A (en) | 1889-04-23 | Dumping-wagon | ||
| US492839A (en) | 1893-03-07 | Key for brake-shoes | ||
| US402150A (en) | 1889-04-30 | Broadcast seed-sower | ||
| US528409A (en) | 1894-10-30 | Denis ahern | ||
| FR2512732A1 (fr) | 1981-09-14 | 1983-03-18 | Raffinage Cie Francaise | Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications |
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| ECSP961635A (es) | 1996-01-11 | 1997-06-27 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| ECSP971998A (es) | 1997-01-15 | 1998-04-07 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| DE19815060A1 (de) | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| WO2001064683A1 (en) | 2000-02-29 | 2001-09-07 | Takeda Chemical Industries, Ltd. | Processes for the production of thienopyrimidine derivatives |
| WO2003064429A1 (en) | 2002-01-30 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Thienopyrimidines, process for preparing the same and use thereof |
| PT1591446E (pt) | 2003-01-29 | 2013-06-12 | Takeda Pharmaceutical | Compostos de tienopirimidina e sua utilização |
| CA2531508C (en) | 2003-07-07 | 2013-10-08 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| KR20080041662A (ko) | 2005-07-22 | 2008-05-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 조기 배란 예방제 |
| TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| NZ580457A (en) | 2007-04-06 | 2012-03-30 | Neurocrine Biosciences Inc | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| KR20160088947A (ko) | 2010-06-16 | 2016-07-26 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
| JP2012077020A (ja) | 2010-09-30 | 2012-04-19 | Mochida Pharmaceut Co Ltd | ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬 |
| PT3415517T (pt) | 2012-09-28 | 2022-05-13 | Takeda Pharmaceuticals Co | Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia |
| WO2014143669A1 (en) | 2013-03-15 | 2014-09-18 | AbbVie Inc . | Compositions for use in treating heavy menstrual bleeding and uterine fibroids |
| FI3263110T3 (fi) | 2015-02-26 | 2023-07-25 | Takeda Pharmaceuticals Co | Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita |
| US9949974B2 (en) | 2015-09-01 | 2018-04-24 | Abbvie Inc. | Methods of adminstering elagolix |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| US11980621B2 (en) | 2017-06-05 | 2024-05-14 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| EP4041738A1 (en) | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN115279769A (zh) | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| EP4243829A1 (en) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| EP4419530A1 (en) | 2021-10-18 | 2024-08-28 | Sumitomo Pharma Switzerland GmbH | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
-
2017
- 2017-09-29 ES ES17823018T patent/ES2912929T5/es active Active
- 2017-09-29 MD MDE20190880T patent/MD3518933T4/ro unknown
- 2017-09-29 HU HUE17823018A patent/HUE059101T2/hu unknown
- 2017-09-29 MX MX2019003726A patent/MX2019003726A/es unknown
- 2017-09-29 SM SM20220254T patent/SMT202200254T1/it unknown
- 2017-09-29 RS RS20220565A patent/RS63300B2/sr unknown
- 2017-09-29 BR BR112019006227-0A patent/BR112019006227A2/pt not_active Application Discontinuation
- 2017-09-29 FI FIEP17823018.1T patent/FI3518933T4/fi active
- 2017-09-29 JP JP2019538721A patent/JP7043503B2/ja active Active
- 2017-09-29 PL PL17823018.1T patent/PL3518933T5/pl unknown
- 2017-09-29 IL IL300580A patent/IL300580B2/en unknown
- 2017-09-29 AU AU2017336363A patent/AU2017336363B2/en active Active
- 2017-09-29 LT LTEPPCT/EP2017/074907T patent/LT3518933T/lt unknown
- 2017-09-29 CA CA3038879A patent/CA3038879A1/en active Pending
- 2017-09-29 HR HRP20220708TT patent/HRP20220708T4/hr unknown
- 2017-09-29 NZ NZ752916A patent/NZ752916A/en unknown
- 2017-09-29 DK DK17823018.1T patent/DK3518933T4/da active
- 2017-09-29 ES ES22162349T patent/ES3018413T3/es active Active
- 2017-09-29 EP EP22162349.9A patent/EP4094766B1/en active Active
- 2017-09-29 PT PT178230181T patent/PT3518933T/pt unknown
- 2017-09-29 SI SI201731123T patent/SI3518933T2/sl unknown
- 2017-09-29 HU HUE22162349A patent/HUE072130T2/hu unknown
- 2017-09-29 WO PCT/EP2017/074907 patent/WO2018060501A2/en not_active Ceased
- 2017-09-29 CN CN201780072987.XA patent/CN110312512B/zh active Active
- 2017-09-29 EP EP17823018.1A patent/EP3518933B2/en active Active
- 2017-09-29 PL PL22162349.9T patent/PL4094766T3/pl unknown
-
2019
- 2019-03-28 IL IL265700A patent/IL265700B2/en unknown
- 2019-03-29 US US16/370,299 patent/US11033551B2/en active Active
-
2021
- 2021-05-11 US US17/317,769 patent/US11793812B2/en active Active
-
2022
- 2022-06-02 CY CY20221100390T patent/CY1125254T1/el unknown
- 2022-07-15 US US17/866,201 patent/US11957684B2/en active Active
- 2022-09-30 AU AU2022241582A patent/AU2022241582C1/en active Active
-
2024
- 2024-01-30 US US18/427,579 patent/US20240165118A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003726A (es) | Metodos para tratar fibroides uterinos y endometriosis. | |
| Chen et al. | Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2024010140A (es) | Nuevos metodos. | |
| AR108202A1 (es) | Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 | |
| NZ745957A (en) | Heterocyclic amides useful as protein modulators | |
| PH12021551290A1 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| EA201201358A1 (ru) | Парентеральная лекарственная форма, высвобождающая ингибиторы ароматазы и гестагены для лечения эндометриоза | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| CY1119661T1 (el) | 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγα, μεθοδοι για την παραγωγη αυτων και χρηση αυτων για την αγωγη παθησεων | |
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| EA201791361A1 (ru) | Терапия антагонистом рецепторов окситоцина в лютеиновую фазу для имплантации и беременности у женщин, проходящих процедуры вспомогательных репродуктивных технологий | |
| PH12017500724B1 (en) | Carbazole derivatives | |
| BR112018075206A2 (pt) | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| PE20210096A1 (es) | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret | |
| MX2010004967A (es) | Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso. | |
| PA8848001A1 (es) | Pirrolidinas | |
| MX2017014844A (es) | Regimen modulador selectivo de los receptores de progesterona (sprm). | |
| MX389041B (es) | Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos. | |
| CY1121190T1 (el) | Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης | |
| EA201990857A1 (ru) | Способы лечения миомы матки и эндометриоза | |
| MA46362B1 (fr) | Méthodes de traitement des fibromes utérins et de l'endométriose | |
| UA95686U (uk) | Лікарський засіб для терапії захворювань передміхурової залози в формі супозиторія |